Did aiming for lower blood pressure prevent more heart and stroke events?

To answer this, the researchers combined 31 randomized controlled trials involving 156,933 adults with hypertension. In each trial, participants had been randomly assigned to either more intensive blood pressure control—usually aiming for a systolic reading (the top number) below about 120 or 130 mmHg—or a standard goal, usually below about 140 mmHg. They were then followed for major cardiovascular events such as heart attack, stroke, or heart-related death. Pooling randomized trials in this way is useful because individual trials can be small, use narrow groups, or have too short a follow-up to answer the question reliably.

What the combined trials found

Across the trials, intensive control was associated with a 20% relative reduction in the risk of major cardiovascular events (risk ratio 0.80; 95% confidence interval 0.75–0.84). In everyday terms, for every group of people with a given event rate under standard targets, the intensive group experienced roughly one fifth fewer events. This difference was too large to be easily explained by chance, and the finding held up when the researchers checked whether any single trial was driving it.

Where the answer is less certain

One important uncertainty is diabetes. In the pooled data, the reduction in major cardiovascular events was attenuated among people with diabetes, and the trials did not show a significant mortality benefit in that group. That is a reason for caution in applying the overall result to everyone with diabetes.

Safety also deserves a closer look. The review focused on cardiovascular benefit and did not systematically analyze harms such as symptomatic low blood pressure, electrolyte disturbances, or acute kidney injury. Intensive treatment carries those potential risks, and the authors emphasized close monitoring of treatment tolerance and adverse effects. The included trials also differed in their exact blood pressure goals, measurement methods, and medication choices, so the pooled result gives a general direction but is not a single prescription for every patient.

In short, the randomized evidence supports lower systolic targets for many people with hypertension, while the diabetes uncertainty and missing safety tally remain important boundaries.